Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Myeloproliferative Neoplasms, Version 2.2017 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., Klisovic, R. B., Kropf, P., Mohan, S. R., Oh, S., Padron, E., Podoltsev, N., Pollyea, D. A., Rampal, R., Rein, L. A., Scott, B., Snyder, D. S., Stein, B. L., Verstovsek, S., Wadleigh, M., Wang, E. S., Bergman, M. A., Gregory, K. M., Sundar, H. 2016; 14 (12): 1572-1611

Abstract

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagnosis and the management of patients with MPNs have evolved since the identification of mutations that activate the JAK pathway (JAK2, CALR, and MPL mutations) and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnostic workup of MPN (MF, PV, and ET), risk stratification, treatment, and supportive care strategies for the management of MF.

View details for Web of Science ID 000389962100011